ELISABET ESTEVE MANASANCH
Title | Assistant Professor |
---|
Institution | MD Anderson |
---|
Department | Lymphoma-Myeloma |
---|
Address | 1400 Holcombe Blvd Houston TX 77030-4008
|
---|
vCard | Download vCard |
---|
|
|
|
Bibliographic
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media.
(Note that publications are often cited in additional ways that are not shown here.)
Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication.
Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication.
Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.)
Click a Field or Translation tag to filter the publications.
-
Ndacayisaba LJ, Rappard KE, Shishido SN, Ruiz Velasco C, Matsumoto N, Navarez R, Tang G, Lin P, Setayesh SM, Naghdloo A, Hsu CJ, Maney C, Symer D, Bethel K, Kelly K, Merchant A, Orlowski R, Hicks J, Mason J, Manasanch EE, Kuhn P. Enrichment-Free Single-Cell Detection and Morphogenomic Profiling of Myeloma Patient Samples to Delineate Circulating Rare Plasma Cell Clones. Curr Oncol. 2022 04 21; 29(5):2954-2972.
PMID: 35621632; PMCID: PMC9139906.
Citations: Fields:
Translation:
HumansCells
-
Patel KK, Shah JJ, Feng L, Lee HC, Manasanch EM, Olsem J, Morphey A, Huo XJ, Thomas SK, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ. Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma. Clin Cancer Res. 2022 04 01; 28(7):1277-1284.
PMID: 34992070; PMCID: PMC9365361.
Citations: Fields:
Translation:
Humans
-
Manasanch EE, Kunacheewa C, Claussen CM, Lee HC, Thomas SK, Gunther J, Pinnix CC, Dabaja BS, Amini B, Alexanian R, Orlowski RZ, Dong W, Feng L, Weber DM. Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up. Blood Cancer J. 2021 02 08; 11(2):17.
PMID: 33563896; PMCID: PMC7873072.
Citations:
2 Fields:
Translation:
Humans
-
Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Olsem J, Crumpton B, Morphey A, Berkova Z, Feng L, Orlowski RZ. Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma. Haematologica. 2020 05; 105(5):e242-e245.
PMID: 31413094; PMCID: PMC7193461.
Citations:
2 Fields:
Translation:
HumansCTClinical Trials
-
Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Feng L, Berkova Z, Hildebrandt M, Orlowski RZ. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial. Lancet Haematol. 2018 Dec; 5(12):e628-e640.
PMID: 30501870.
Citations:
6 Fields:
Translation:
HumansCTClinical Trials
-
Becnel M, Manasanch EE. Myeloma patients: genes increase risk for osteonecrosis of the jaw. Leuk Lymphoma. 2017 10; 58(10):2271-2272.
PMID: 28614996.
Citations: Fields:
Translation:
Humans
-
Manasanch EE. Recommend maintenance therapy with lenalidomide in multiple myeloma. Semin Oncol. 2016 Dec; 43(6):712-713.
PMID: 28061994.
Citations:
1 Fields:
Translation:
Humans
-
Manasanch EE, Korde N, Mailankody S, Tageja N, Bhutani M, Roschewski M, Landgren O. Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials. Haematologica. 2014 Dec; 99(12):1769-71.
PMID: 25472951; PMCID: PMC4258744.
Citations: Fields:
Translation:
Humans
-
Tembhare PR, Yuan CM, Venzon D, Braylan R, Korde N, Manasanch E, Zuchlinsky D, Calvo K, Kurlander R, Bhutani M, Tageja N, Maric I, Mulquin M, Roschewski M, Kwok M, Liewehr D, Landgren O, Stetler-Stevenson M. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leuk Res. 2014 Mar; 38(3):371-6.
PMID: 24462038; PMCID: PMC3947595.
Citations:
33 Fields:
Translation:
HumansCells
-
Cherry BM, Costello R, Zingone A, Burris J, Korde N, Manasanch E, Kwok M, Annunziata C, Roschewski MJ, Engels EA, Landgren O. Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age. Am J Hematol. 2013 Feb; 88(2):89-92.
PMID: 23169485; PMCID: PMC5572208.
Citations:
3 Fields:
Translation:
Humans
-
Pre-transplant bone marrow myeloma cells. Leukemia and Lymphoma. 1-2.
-
Kidney actinomycosis, a rare diagnosis that can mimic renal cell carcinoma. Infectious Diseases in Clinical Practice. 20:362-364.
-
Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease. Leukemia and Lymphoma. 1-8.
-
Annals of Hematology.
-
Management of heavy chain diseases. ONCOLOGY (United States). 28.
-
Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer.
-
Gefitinib and erlotinib in metastatic non-small cell lung cancer. Oncologist. 20:400-410.
-
Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell.
-
Myc is also the bad guy in myeloma. Leukemia and Lymphoma. 1-2.
-
Recommend maintenance therapy with lenalidomide in multiple myeloma. Seminars in Oncology. 43:712-713.
-
Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 22:2159-2164.
-
Myeloma imaging. Leukemia and Lymphoma. 1-2.
-
Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone. Leukemia and Lymphoma. 1-10.
This graph shows the total number of publications by year. To see the data as text,
click here.
This graph shows the total number of publications by year. To return to the graph,
click here.
Year | Publications |
---|
2012 | 1 |
2013 | 1 |
2014 | 1 |
2016 | 1 |
2017 | 1 |
2018 | 1 |
2019 | 1 |
2021 | 1 |
2022 | 2 |
This graph shows the number and percent of publications by field.
Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications.
Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written.
To see the data as text,
click here.
This graph shows the number and percent of publications by field.
Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications.
Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written.
To see the data as text,
click here.
newest
oldest
line numbers
double spacing
all authors
publication IDs